Blood glucose management stratification: 1, HbA1c <7.5% monotherapy (insulin sensitizer "Metformin", etc.), 2, HbA1c >7.5% two drugs (sulfonylurea + insulin sensitizer), 3, HbA1c >9% two drugs or three drugs (sulfonylurea + biguanide + baixin), we found that the patient’s glycated hemoglobin in the above 2, 3 and no hypoglycemic reaction Basal insulin should be used if the patient’s glycemic hemoglobin is below 8%, the basal insulin dosage is 0.1-0.2U/Kg; if the HbA1c is above 8%, the basal insulin dosage is 0.2-0.3U/Kg, adjusted every 2-3 days. Insulin dose to achieve the goal of blood glucose control, fixed protocol, basal insulin increased by 2 U. And normalization of fasting blood glucose is the primary goal of glycated hemoglobin attainment, 1. fasting GLU>10mmol, increased by 4 U; 2. fasting GLU7.8-10mmol/L, increased by 2 U; 3. fasting GLU6.1-7.7mmol/L, increased by 1 U. If occurrence of Hypoglycemia: 1. GLU<3.9mmol/L, basal insulin decrease by 10%-20%, 2. GLU<2.2 mmol/L, basal insulin decrease by 20%-40%, follow fasting then postprandial, basal insulin (TDD) is better than premixed insulin (Nph), and low incidence of hypoglycemia risk, generally obese patients with poor fasting glucose start: basal Insulin 12u qn + Gevalt 0.5g qd + Imodium 3mg or Gliclazide extended-release tablets 10mg qd, Gevalt can reduce insulin dosage, reduce body weight and increase insulin sensitivity, after which the dose is adjusted as appropriate according to the patient's fasting glucose and glycosylated hemoglobin with the above insulin application, and the patient is advised to eat less and eat more, reduce body weight and increase exercise.